| Active Not Recruiting | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients W NCT06901505 | Akebia Therapeutics | Phase 3 |
| Not Yet Recruiting | Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients NCT06352138 | Megalabs | Phase 3 |
| Withdrawn | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic NCT05082571 | Akebia Therapeutics | Phase 3 |
| Withdrawn | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic NCT05082584 | Akebia Therapeutics | Phase 3 |
| Active Not Recruiting | Vafseo Outcomes In-Center Experience NCT06520826 | USRC Kidney Research | Phase 3 |
| Recruiting | Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients NCT06463236 | Hong Daqing | N/A |
| Recruiting | A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis NCT06466785 | Genexine, Inc. | Phase 3 |
| Recruiting | A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects Wit NCT05515367 | Zydus Lifesciences Limited | Phase 4 |
| Active Not Recruiting | Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Ane NCT05745883 | Disc Medicine, Inc | Phase 1 |
| Unknown | Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients NCT05900635 | Alexandria University | Phase 4 |
| Active Not Recruiting | Oral Iron Supplementation for Patients With Chronic Kidney Disease NCT05544513 | Universidade Federal Fluminense | Phase 2 |
| Completed | Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease NCT06556134 | Centre Hospitalier Hassan II - Fès | Phase 4 |
| Completed | A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron NCT04655027 | AstraZeneca | Phase 4 |
| Unknown | Roxadustat for Anemia in Patients With CKD NCT04502537 | Shenzhen Second People's Hospital | — |
| Completed | Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients NCT05699109 | Helwan University | — |
| Completed | Desidustat in the Treatment of Chemotherapy Induced Anemia NCT04667533 | Zydus Lifesciences Limited | Phase 1 |
| Completed | PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD NCT04543812 | Panion & BF Biotech Inc. | Phase 3 |
| Completed | Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory NCT05698420 | Sanliurfa Mehmet Akif Inan Education and Research Hospital | — |
| Withdrawn | Project Aura: Co-design of a Home-based Monitoring Service NCT04112615 | Entia Ltd | — |
| Completed | Iron Dosing Pilot Study Using Model Predictive Control NCT03633656 | University of Louisville | Phase 4 |
| Completed | A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patient NCT04027517 | JW Pharmaceutical | Phase 3 |
| Suspended | Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Pati NCT03193073 | Omnia Mohammed Hashem | N/A |
| Completed | Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease NCT04036253 | Bio Sidus SA | Phase 3 |
| Completed | Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With NCT04959578 | Rufaida Mazahir | Phase 4 |
| Completed | Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients? NCT03731741 | Tanta University | Phase 2 |
| Completed | Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients NCT03325621 | Pieris Pharmaceuticals GmbH | Phase 1 / Phase 2 |
| Completed | Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Dis NCT03427801 | Chinese University of Hong Kong | — |
| Unknown | Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients NCT02754167 | Pieris Pharmaceuticals GmbH | Phase 1 / Phase 2 |
| Completed | Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis NCT02805244 | Akros Pharma Inc. | Phase 1 |
| Completed | Periodic Versus Continuous IV Iron Supplementation in HD Patients NCT02787824 | Papageorgiou General Hospital | Phase 4 |
| Unknown | To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) NCT03521713 | Dong-A ST Co., Ltd. | Phase 3 |
| Completed | Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease NCT02581124 | Akros Pharma Inc. | Phase 1 |
| Completed | CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis NCT03428594 | Chong Kun Dang Pharmaceutical | Phase 3 |
| Completed | CKD-11101 Phase 3 SC Study NCT03431623 | Chong Kun Dang Pharmaceutical | Phase 3 |
| Completed | KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD NCT02268994 | Keryx Biopharmaceuticals | Phase 3 |
| Completed | Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients NCT02198495 | Medical University of Vienna | Phase 4 |
| Completed | A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia NCT02128074 | Keryx Biopharmaceuticals | Phase 2 |
| Completed | Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease NCT01971164 | Akros Pharma Inc. | Phase 1 |
| Completed | Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease NCT01532349 | Johns Hopkins University | Phase 2 |